|
||
| |||||||
London, UK, 27 September 2005 Lipoxen Technologies Ltd, the drug and vaccine delivery company, has signed major research and product collaboration agreements with Baxter Healthcare Corp, the Serum Institute of India and National Biotechnologies OAO. The recent collaboration agreement with Baxter Healthcare (NYSE:BAX) will focus on an initial seven month research period to investigate the effectiveness of conjugating Baxter’s proprietary proteins with PolyXen®, Lipoxen’s proprietary technology. PolyXen is a natural polymer (polysialic acid) that can prolong the active life and improve the pharmacokinetics of conventional drugs and biologicals. It is considered a next generation drug delivery technology. Lipoxen has also finalised an extended agreement with its current partner the Serum Institute of India, expanding the number of blockbuster drugs the two companies are collaborating on, and facilitating access to the major Western markets. These products include erythropoietin (EPO), paclitaxel and a pneumococcal vaccine. Additionally, Lipoxen will receive an initial $750,000 in upfront payments plus royalties from National Biotechnologies OAO for licensing Lipoxen’s proprietary extended release insulin and interferon product candidates for Russia, Ukraine and Kazakhstan markets. Scott Maguire, CEO of Lipoxen said “These new agreements, along with our existing agreements with three of the four world’s largest biotechnology companies, mean these are very exciting times for Lipoxen and the combination of cutting edge proprietary technologies, strategic partnerships and a broad product candidate portfolio translates into a very strong business backed by very compelling science. The quality of our partners underlines the potential of our drug delivery technologies.” Norbert Riedel, Ph.D., CSO at Baxter commented “Baxter continues to apply its own scientific resources and leverage strategic collaborations with biotechnology companies, in order to improve haemophilia therapy. This agreement with Lipoxen reflects our focus on advancing haemophilia therapy and evaluating promising technologies aimed at extending the duration of action of blood clotting factors.” Dr Kapre, CEO of SIIL, said “Our agreement now expands the reach of our collaboration for four potential blockbuster candidates to the major Western markets, including US, Europe and Japan. SIIL considers the Lipoxen partnership as playing a critical role in accessing these drug and vaccine markets.” END NOTES TO EDITORS Lipoxen Technologies has a broad portfolio of delivery technologies for drugs and vaccines as well as expertise to assist and enable pharmaceutical and biotechnology companies to optimise the performance of their drugs and vaccines, improve delivery, extend product franchises, and fuel their product pipelines. PolyXen® is a multifaceted platform technology that employs the natural polymer polysialic acid (PSA) to prolong the active life and improve the pharmacokinetics of therapeutic proteins and peptides, as well as conventional drugs. PolyXen is considered a next generation to PEGylation. ImuXen®, Lipoxen’s other proprietary technology platform employs novel liposome constructs to boost the effectiveness of DNA, protein and polysaccharide vaccines. ImuXen can achieve in a single dose with conventional vaccine antigens protective immunity which otherwise requires multiple doses. Lipoxen has 11 proprietary product candidates in development/preclinical phase. These candidates include insulin, interferon, EPO, and hepatitis B and pneumococcal vaccines. The Company also has collaborations with three of the world’s largest biotech companies and some of the world’s largest generics and vaccine companies. For more information on Lipoxen visit www.lipoxen.co.uk Baxter International Inc. (NYSE:BAX) is a global biotechnology medical device and specialty pharmaceutical company. For more information visit www.baxter.com Serum Institute of India Ltd (SIIL) is the largest exporter of vaccines and immuno-biologicals in India with its products being exported to 138 countries across the globe. The company contributes to a number of global vaccination programmes and has gained worldwide recognition as a reliable source of quality vaccines. Its export performance has also earned the company international recognition as an Export and Trading House. Founded in 1998, National Biotechnologies OAO (NBT) has grown to become one of the largest protein drug manufacturers in Central and Eastern Europe. The company has developed a number of patented manufacturing technologies including a high output human insulin manufacturing technique. One of the Company’s aims is to improve production output of insulin reducing Russia’s reliance on foreign imports. FOR MORE INFORMATION Lipoxen Technologies 0207 953 0572 Scott Maguire, CEO Dr Peter Laing, Director of Business Development Northbank (Trade and Financial Enquiries) 0207 886 8150 Emma Palmer Rowan Minnion WMC (Media Enquiries) 0207 930 9030 Charlie Geller
Alex Glover |
|
| ||||||||
